E-LIB Suche - Ergebnisse für: Sonja Zweegman

1

Ixazomib-Thalidomide-low dose dexamethasone induction follo..:

Sonja Zweegman ; Claudia A.M. Stege ; Einar Haukas...
Haematologica. 105 (2020) 12 - p. 2879-2882 , 2020

Link: https://doi.org/10.3324/..

2

Bortezomib, thalidomide, and dexamethasone with or without ..:

Moreau, Philippe ; Hulin, Cyrille ; Perrot, Aurore...
The Lancet Oncology. , 2024

Link: https://doi.org/10.1016/..

3

The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety ..:

Hillengass, Jens ; Cohen, Adam D. ; Agha, Mounzer...
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S36-S37 , 2024

Link: https://doi.org/10.1016/..

4

HOVON 104, long‐term follow‐up of bortezomib‐dexamethasone ..:

Minnema, Monique C. ; Nasserinejad, Kazem ; Hegenbart, Ute...
eJHaem. , 2024

Link: https://doi.org/10.1002/..

5

Predictors of early morbidity and mortality in newly diagno..:

Mai, Elias K. ; Hielscher, Thomas ; Bertsch, Uta...
Leukemia. 38 (2023) 3 - p. 640-647 , 2023

Link: https://doi.org/10.1038/..

6

NK Cell Phenotype Is Associated With Response and Resistanc..:

Verkleij, Christie P.M. ; Frerichs, Kristine A. ; Broekmans, Marloes E.C....
HemaSphere. 7 (2023) 5 - p. e881 , 2023

Link: https://doi.org/10.1097/..

7

Teclistamab impairs humoral immunity in patients with heavi..:

Frerichs, Kristine A. ; Verkleij, Christie P. M. ; Mateos, Maria Victoria...
Blood Advances. 8 (2023) 1 - p. 194-206 , 2023

Link: https://doi.org/10.1182/..

8

P-380 Immunological aging is associated with worse clinical..:

Bruins, Wassilis ; Duetz, Carolien ; Groen, Kaz...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S249-S250 , 2023

Link: https://doi.org/10.1016/..

9

T-cell redirecting bispecific and trispecific antibodies in..:

van de Donk, Niels W.C.J. ; O'Neill, Chloe ; de Ruijter, Maaike E.M...
Current Opinion in Oncology. 35 (2023) 6 - p. 601-611 , 2023

Link: https://doi.org/10.1097/..

10

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR..:

Roeten, Margot ; van Dijk, Suzanne ; van Meerloo, Johan...
HemaSphere. 7 (2023) S3 - p. e81299a0 , 2023

Link: https://doi.org/10.1097/..

11

Prevention and management of adverse events during treatmen..:

Ludwig, Heinz ; Terpos, Evangelos ; van de Donk, Niels...
The Lancet Oncology. 24 (2023) 6 - p. e255-e269 , 2023

Link: https://doi.org/10.1016/..

12

Ixazomib, daratumumab and low-dose dexamethasone in interme..:

Groen, Kaz ; Stege, Claudia A.M. ; Nasserinejad, Kazem...
eClinicalMedicine. 63 (2023) - p. 102167 , 2023

Link: https://doi.org/10.1016/..

13

S187: IMMUNOLOGICAL AGING HAS A NEGATIVE IMPACT ON CLINICAL..:

Bruins, Wassilis ; Duetz, Carolien ; Groen, Kaz...
HemaSphere. 7 (2023) S3 - p. e28577c3 , 2023

Link: https://doi.org/10.1097/..

14

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CEL..:

Minnema, Monique ; Nasserinejad, Kazem ; Hegenbart, Ute...
HemaSphere. 7 (2023) S3 - p. e50569c6 , 2023

Link: https://doi.org/10.1097/..

15

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ix..:

Groen, Kazimierz ; Schjesvold, Fredrik H. ; van der Holt, Bronno...
HemaSphere. 7 (2023) 9 - p. e940 , 2023

Link: https://doi.org/10.1097/..